Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More

2026-03-11T15:42:05-04:00January 20th, 2026|Press Releases|
Go to Top